Subscribe to our Newsletters !!
Survival in the prehistoric world was rather chall
Have you added sugar to your tea or salt to your s
This doesn't feel like another one of my English e
New Delhi, India – April 27, 2025 - An Indian co
Alembic Pharmaceuticals Limited (Alembic) announce
For some time now,
Dear Readers, Welcome to the latest issue of The Magazine
Suven Life Sciences, Hyderabad India based pharmaceutical company gets patent approval from Newzealand and Norway for its product related with Neurogenerative Disease treatment.
The company informed that, these patents are valid till 2034 and 2027, respectively, the company said in a BSE filing.
rnrn
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added. .
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life CEO Venkat Jasti said.
The granted claims of patents are being developed as therapeutic agents useful in treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson's and schizophrenia, it added.
